Volume 27, Number 8—August 2021
CME ACTIVITY - Synopsis
Four Human Cases of Eastern Equine Encephalitis in Connecticut, USA, during a Larger Regional Outbreak, 2019
Table
Characteristics and diagnostic testing | Case 1 |
Case 2 |
Case 3 |
Case 4 |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Age, y/sex | 77/F | 73/M | 64/M | 42/M | |||||||
Date of illness onset | Aug 28 | Sep 11 | Sep 12 | Aug 21 | |||||||
Signs and symptoms | Fever, confusion, headache, shock, coma, seizures, flaccid paralysis | Stupor, left-sided weakness | Fever, right arm clumsiness; rapid progression to coma | Neck pain, fever, dysarthria, confusion, seizures | |||||||
Day of brain MRI; result |
Day 4; diffuse T2 hyperintensity cerebrum, cerebellum, brainstem |
Day 4; hyperintensity bilateral basal ganglia, right occipital regions |
Day 5; left thalamic enhancement, T2 hyperintensity temporal lobe |
Day 3; leptomeningeal enhancement right frontal and parietal lobes, T1 hyperintense signal globi pallidi |
|||||||
Days postadmission |
|||||||||||
Laboratory findings | 3 |
7 |
13 |
2 |
4 |
9 |
2† |
4 |
2 |
9 |
21 |
CSF values | |||||||||||
Protein, mg/dL | 90 | 238 | 94 | 112 | 119 | 174 | 108 | 146 | 236 | 288 | ND |
Glucose, mg/dL | 57 | 74 | 53 | 62 | 64 | 81 | 65 | 78 | 225 | 79 | ND |
Leukocytes/mm3 | 60‡ | 13 | 9 | 428 | 62 | 40 | 1,162 | 33 | 343 | 142 | 13 |
Neutrophils, % | 22 | 2 | 0 | 86 | 9 | 0 | 76 | 8 | 80 | 0 | 2 |
Lymphocytes, % | 38 | 73 | 100 | 9 | 78 | 85 | 11 | 87 | 14 | 89 | 79 |
Immunoassay, CSF | |||||||||||
Reference lab§ | |||||||||||
IgM IFA | – | ND | ND | ND | – | ND | ND | – | ND | – | ND |
IgG IFA | – | ND | ND | ND | – | ND | ND | – | ND | – | ND |
CDC | |||||||||||
IgM MIA | + | ND | ND | ND | + | ND | ND | + | ND | + | + |
PRNT¶ | 1:4 | ND | ND | ND | 1:32 | ND | ND | 1:16 | ND | ND | 1:4,096# |
Immunoassay, serum | |||||||||||
Reference lab** | Day 7 |
||||||||||
IgM IFA | – | ND | ND | ND | ND | ND | ND | – | ND | ND | ND |
IgG IFA | – | ND | ND | ND | ND | ND | ND | +; 1:16 |
ND | ND | ND |
CDC | Day 6 |
||||||||||
IgM MIA | ND | ND | ND | ND | ND | ND | ND | + | ND | ND | ND |
PRNT# |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
Outcome | Death on day 22 |
Death on day 10 |
Death on day 8 |
Severe sequelae |
*CDC, Centers for Disease Control and Prevention; CSF, cerebrospinal fluid; IFA, indirect immunofluorescence assay; lab, laboratory; MIA, microparticle immunoassay; ND, not done; PRNT, plaque reduction neutralization test; –, negative; +, positive. †CSF from outside hospital laboratory before transfer. ‡CSF with 40% mononuclear cells. §CSF IFA >1:4 is positive. ¶CSF PRNT >1:2 is positive. #CSF contaminated with blood. **Serum IFA >1:16 positive.
1These authors contributed equally to this article.
2Current affiliation: University of Hawai’i, Honolulu, Hawaii, USA.
3Current affiliation: University of Texas Health Science Center San Antonio, Texas, USA.
Page created: May 27, 2021
Page updated: July 21, 2021
Page reviewed: July 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.